findmyKOL
Clinical trialNCT03357757CompletedPhase 2Interventional

Avelumab With Valproic Acid in Virus-associated Cancer

SponsorAHS Cancer Control AlbertaEnrollment39Cancer That is Associated With a Chronic Viral InfectionEBER Positive Hodgkins and Non-hodgkins LymphonaEBER Positive NPCSquamous Cell Carcinoma of the Cervixp16 Positive SCCHNp16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Cross Cancer Institute

    Edmonton, Alberta, Canada

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Feb 2018
Primary completion
30 Mar 2022
Completion
31 Mar 2025
Last update posted
26 Jun 2025
Registered enrollment
39
Registry id
NCT03357757
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.